An intronic variant in OPRD1 predicts treatment outcome for opioid dependence in African-Americans

Neuropsychopharmacology

Volumn 38, Issue 10, 2013, Pages 2003-2010

  Crist, Richard C ^a   Clarke, Toni Kim ^a   Ang, Alfonso ^b   Ambrose Lanci, Lisa M ^a   Lohoff, Falk W ^a   Saxon, Andrew J ^c   Ling, Walter ^b   Hillhouse, Maureen P ^b   Bruce, R Douglas ^d   Woody, George ^a   Berrettini, Wade H ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c VA PUGET SOUND HEALTH CARE SYSTEM   (United States)

^d YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

buprenorphine; methadone; pharmacogenetics; treatment outcome

Indexed keywords

BUPRENORPHINE PLUS NALOXONE; METHADONE; OPRD1 PROTEIN; REGULATOR PROTEIN; UNCLASSIFIED DRUG;

ADULT; AFRICAN AMERICAN; ARTICLE; CONTROLLED STUDY; DRUG DEPENDENCE TREATMENT; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG MEGADOSE; DRUG URINE LEVEL; EUROPEAN AMERICAN; FEMALE; GENE LOCUS; GENETIC ASSOCIATION; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE; HUMAN; INTRON; MAJOR CLINICAL STUDY; MALE; MENTAL PATIENT; OBSERVATIONAL STUDY; OPEN STUDY; OPIATE ADDICTION; OUTCOME ASSESSMENT; PHARMACOGENETICS; PREDICTIVE VALUE; PREVALENCE; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; RANDOMIZED CONTROLLED TRIAL; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT DURATION; TREATMENT OUTCOME; URINALYSIS;

ADULT; AFRICAN AMERICANS; ANALGESICS, OPIOID; BUPRENORPHINE; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENOTYPE; HUMANS; INTRONS; MALE; METHADONE; MIDDLE AGED; NALOXONE; NARCOTIC ANTAGONISTS; NARCOTICS; OPIOID-RELATED DISORDERS; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, OPIOID, DELTA; TREATMENT OUTCOME;

EID: 84882448800     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1038/npp.2013.99     Document Type: Article

References (54)

1. Amass L, Bickel WK, Crean JP, Blake J, Higgins ST (1998). Alternateday buprenorphine dosing is preferred to daily dosing by opioiddependent humans. Psychopharmacology (Berl) 136: 217-225.
2. Ashenhurst JR, Bujarski S, Ray LA (2012). Delta and kappa opioid receptor polymorphisms influence the effects of naltrexone on subjective responses to alcohol. Pharmacol Biochem Behav 103: 253-259.
3. Barrett JC, Fry B, Maller J, Daly MJ (2005). Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics (Oxford, England) 21: 263-265.
4. Bayerer B, Stamer U, Hoeft A, Stuber F (2007). Genomic variations and transcriptional regulation of the human mu-opioid receptor gene. Eur J Pain 11: 421-427.
5. Belcheva MM, Barg J, McHale RJ, Dawn S, Ho MT, Ignatova E et al (1993). Differential down- and up-regulation of rat brain opioid receptor types and subtypes by buprenorphine. Mol Pharmacol 44: 173-179.
6. Benjamini Y, Drai D, Elmer G, Kafkafi N, Golani I (2001). Controlling the false discovery rate in behavior genetics research. Behav Brain Res 125: 279-284.
7. Birnbaum HG, White AG, Schiller M, Waldman T, Cleveland JM, Roland CL (2011). Societal costs of prescription opioid abuse, dependence, and misuse in the United States. Pain Med 12: 657-667.
8. Bradford LD (2002). CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants. Pharmacogenomics 3: 229-243.
9. Brewer DD, Catalano RF, Haggerty K, Gainey RR, Fleming CB (1998). A meta-analysis of predictors of continued drug use during and after treatment for opiate addiction. Addiction 93: 73-92.
10. Crettol S, Besson J, Croquette-Krokar M, Hammig R, Gothuey I, Monnat M et al (2008). Association of dopamine and opioid receptor genetic polymorphisms with response to methadone maintenance treatment. Prog Neuropsychopharmacol Biol Psychiatry 32: 1722-1727.
11. Crettol S, Deglon JJ, Besson J, Croquette-Krokar M, Hammig R, Gothuey I et al (2006). ABCB1 and cytochrome P450 genotypes and phenotypes: influence on methadone plasma levels and response to treatment. Clin Pharmacol Ther 80: 668-681.
12. Crist RC, Ambrose-Lanci LM, Vaswani M, Clarke TK, Zeng A, Yuan C et al (2012). Case-control association analysis of polymorphisms in the delta-opioid receptor, OPRD1, with cocaine and opioid addicted populations. Drug Alcohol Depend 127: 122-128.
13. Di Chiara G, Imperato A (1988). Opposite effects of mu and kappa opiate agonists on dopamine release in the nucleus accumbens and in the dorsal caudate of freely moving rats. J Pharmacol Exp Ther 244: 1067-1080.
14. Fiellin DA, O'Connor PG, Chawarski M, Pakes JP, Pantalon MV, Schottenfeld RS (2001). Methadone maintenance in primary care: a randomized controlled trial. JAMA 286: 1724-1731.
15. Filliol D, Ghozland S, Chluba J, Martin M, Matthes HW, Simonin F et al (2000). Mice deficient for delta- and mu-opioid receptors exhibit opposing alterations of emotional responses. Nat Genet 25: 195-200.
16. Franke P, Nothen MM, Wang T, Neidt H, Knapp M, Lichtermann D et al (1999). Human delta-opioid receptor gene and susceptibility to heroin and alcohol dependence. Am J Med Genet 88: 462-464.
17. Fudala PJ, Yu E, Macfadden W, Boardman C, Chiang CN (1998). Effects of buprenorphine and naloxone in morphine-stabilized opioid addicts. Drug Alcohol Depend 50: 1-8.
18. Herz A (1998). Opioid reward mechanisms: a key role in drug abuse? Can J Physiol Pharmacol 76: 252-258.
19. Huang P, Kehner GB, Cowan A, Liu-Chen LY (2001). Comparison of pharmacological activities of buprenorphine and norbuprenorphine: norbuprenorphine is a potent opioid agonist. J Pharmacol Exp Ther 297: 688-695.
20. Hung CC, Chiou MH, Huang BH, Hsieh YW, Hsieh TJ, Huang CL et al (2011). Impact of genetic polymorphisms in ABCB1, CYP2B6, OPRM1, ANKK1 and DRD2 genes on methadone therapy in Han Chinese patients. Pharmacogenomics 12: 1525-1533.
21. Janecka A, Fichna J, Janecki T (2004). Opioid receptors and their ligands. Curr Top Med Chem 4: 1-17.
22. Johnson RE, Eissenberg T, Stitzer ML, Strain EC, Liebson IA, Bigelow GE (1995). Buprenorphine treatment of opioid dependence: clinical trial of daily versus alternate-day dosing. Drug Alcohol Depend 40: 27-35.
23. Kajiwara M, Aoki K, Ishii K, Numata H, Matsumiya T, Oka T (1986). Agonist and antagonist actions of buprenorphine on three types of opioid receptor in isolated preparations. Jpn J Pharmacol 40: 95-101.
24. Levran O, Londono D, O'Hara K, Nielsen DA, Peles E, Rotrosen J et al (2008). Genetic susceptibility to heroin addiction: a candidate gene association study. Genes Brain Behav 7: 720-729.
25. Levran O, Peles E, Hamon S, Randesi M, Adelson M, Kreek MJ (2011). CYP2B6 SNPs are associated with methadone dose required for effective treatment of opioid addiction. Addict Biol; e-pub ahead of print. doi:10.1111/j.1369-1600. 2011.00349.x.
26. Liang KYZ, Zeger SL (1986). Longitudinal data analysis using generalized linear models. Biometrika 73: 13-22.
27. Ling W, Wesson DR, Charuvastra C, Klett CJ (1996). A controlled trial comparing buprenorphine and methadone maintenance in opioid dependence. Arch Gen Psychiatry 53: 401-407.
28. Liu JG, Liao XP, Gong ZH, Qin BY (1999). Methadone-induced desensitization of the delta-opioid receptor is mediated by uncoupling of receptor from G protein. Eur J Pharmacol 374: 301-308.
29. Loh el W, Fann CS, Chang YT, Chang CJ, Cheng AT (2004). Endogenous opioid receptor genes and alcohol dependence among Taiwanese Han. Alcohol Clin Exp Res 28: 15-19.
30. Mattick RP, Kimber J, Breen C, Davoli M (2008). Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev(2): CD002207.
31. Mayer P, Rochlitz H, Rauch E, Rommelspacher H, Hasse HE, Schmidt S et al (1997). Association between a delta opioid receptor gene polymorphism and heroin dependence in man. Neuroreport 8: 2547-2550.
32. Montgomery SB, Sammeth M, Gutierrez-Arcelus M, Lach RP, Ingle C, Nisbett J et al (2010). Transcriptome genetics using second generation sequencing in a Caucasian population. Nature 464: 773-777.
33. Morinville A, Cahill CM, Esdaile MJ, Aibak H, Collier B, Kieffer BL et al (2003). Regulation of delta-opioid receptor trafficking via mu-opioid receptor stimulation: evidence from mu-opioid receptor knock-out mice. J Neurosci 23: 4888-4898.
34. Negus SS, Bidlack JM, Mello NK, Furness MS, Rice KC, Brandt MR (2002). Delta opioid antagonist effects of buprenorphine in rhesus monkeys. Behav Pharmacol 13: 557-570.
35. Nelson EC, Lynskey MT, Heath AC, Wray N, Agrawal A, Shand FL et al (2012). Association of OPRD1 polymorphisms with heroin dependence in a large case-control series. Addict Biol; e-pub ahead of print. doi:10.1111/j.1369-1600. 2012.00445.x.
36. Nicholls L, Bragaw L, Ruetsch C (2010). Opioid dependence treatment and guidelines. J Manag Care Pharm 16(1 Suppl B): S14-S21.
37. Nielsen DA, Ji F, Yuferov V, Ho A, He C, Ott J et al (2010). Genome-wide association study identifies genes that may contribute to risk for developing heroin addiction. Psychiatric Genet 20: 207-214.
38. Oneda B, Crettol S, Bochud M, Besson J, Croquette-Krokar M, Hammig R et al (2011). Beta-arrestin2 influences the response to methadone in opioid-dependent patients. Pharmacogenomics J 11: 258-266.
39. Pani PP, Maremmani I, Pirastu R, Tagliamonte A, Gessa GL (2000). Buprenorphine: a controlled clinical trial in the treatment of opioid dependence. Drug Alcohol Depend 60: 39-50.
40. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D et al (2007). PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 81: 559-575.
41. Rady JJ, Portoghese PS, Fujimo JM (2002). Methadone and heroin antinociception: predominant delta-opioid-receptor responses in methadone-tolerant mice. Jpn J Pharmacol 88: 319-331.
42. Saxon AJ, Ling W, Hillhouse M, Thomas C, Hasson A, Ang A et al (2013). Buprenorphine/Naloxone and methadone effects on laboratory indices of liver health: A randomized trial. Drug Alcohol Depend 128: 71-76.
43. Sibille KT, Kindler LL, Glover TL, Gonzalez RD, Staud R, Riley JL 3rd et al (2011). Individual differences in morphine and butorphanol analgesia: a laboratory pain study. Pain Med 12: 1076-1085.
44. Strain EC, Bigelow GE, Liebson IA, Stitzer ML (1999). Moderate- vs high-dose methadone in the treatment of opioid dependence: a randomized trial. JAMA 281: 1000-1005.
45. Substance Abuse and Mental Health Services Administration, Results from the 2010 National Survey on Drug Use and Health: Summary of National Findings, NSDUH Series H-41, HHS Publication No. (SMA) 11-4658. Rockville, MD: Substance Abuse and Mental Health Services Administration, 2011.
46. Toskulkao T, Pornchai R, Akkarapatumwong V, Vatanatunyakum S, Govitrapong P (2010). Alteration of lymphocyte opioid receptors in methadone maintenance subjects. Neurochem Int 56: 285-290.
47. Wood PL, Charleson SE, Lane D, Hudgin RL (1981). Multiple opiate receptors: differential binding of mu, kappa and delta agonists. Neuropharmacology 20: 1215-1220.
48. Woody GE, Poole SA, Subramaniam G, Dugosh K, Bogenschutz M, Abbott P et al (2008). Extended vs short-term buprenorphinenaloxone for treatment of opioid-addicted youth: a randomized trial. JAMA 300: 2003-2011.
49. Xuei X, Flury-Wetherill L, Bierut L, Dick D, Nurnberger J Jr, Foroud T et al (2007). The opioid system in alcohol and drug dependence: family-based association study. Am J Med Genet B Neuropsychiatr Genet 144B: 877-884.
50. Yekkirala AS, Banks ML, Lunzer MM, Negus SS, Rice KC, Portoghese PS (2012). Clinically employed opioid analgesics produce antinociception via m-d opioid receptor heteromers in Rhesus monkeys. ACS Chem Neurosci 3: 720-727.
51. Zhang H, Gelernter J, Gruen JR, Kranzler HR, Herman AI, Simen AA (2010). Functional impact of a single-nucleotide polymorphism in the OPRD1 promoter region. J Hum Genet 55: 278-284.
52. Zhang H, Kranzler HR, Yang BZ, Luo X, Gelernter J (2008). The OPRD1 and OPRK1 loci in alcohol or drug dependence: OPRD1 variation modulates substance dependence risk. Mol Psychiatry 13: 531-543.
53. Zhang Y, Kim TH, Niswander L (2012). Phactr4 regulates directional migration of enteric neural crest through PP1, integrin signaling, and cofilin activity. Genes Dev 26: 69-81.
54. Zhu Y, King MA, Schuller AG, Nitsche JF, Reidl M, Elde RP et al (1999). Retention of supraspinal delta-like analgesia and loss of morphine tolerance in delta opioid receptor knockout mice. Neuron 24: 243-252..